New Perspectives on Antimicrobial Agents: Long-Acting Lipoglycopeptides.

ABSTRACT: The long-acting lipoglycopeptides (LGPs) dalbavancin and oritavancin are semisynthetic antimicrobials with broad and potent activity against Gram-positive bacterial pathogens. While they are approved by the Food and Drug Administration for acute bacterial skin and soft tissue infections, their pharmacological properties suggest a potential role of these agents for the treatment of deep-seated and severe infections, such as bloodstream and bone and joint infections. The use of these antimicrobials is particularly appealing when prolonged therapy, early discharge, and avoidance of long-term intravascular catheter access are desirable or when multidrug-resistant bacteria are suspected. This review describes the current evidence for the use of oritavancin and dalbavancin in the treatment of in

SUBMITTER: Tran TT 

PROVIDER: S-EPMC9211417 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature